Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China

References

• Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
   Web of Science ®Google Scholar
• Phillips MR, Zhang J, Shi Q, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009;373(9680):2041–2053.
   Web of Science ®Google Scholar
• Montgomery W, Liu L, Stensland MD, et al. The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy. Clin Outcomes Res. 2013;5:407–418.
   PubMedGoogle Scholar
• Liu T, Song X, Chen G, et al. Prevalence of schizophrenia disability and associated mortality among Chinese men and women. Psychiatry Res. 2014;220:181–187.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3):132–191.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71–93.
   PubMed Web of Science ®Google Scholar
• Lin J, Chen G, Guan B, et al. The compliance of schizophrenic patients and factors that affect it. Chin J Nerv Ment Dis. 2000;26:152–155.
   Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes. 2009;2:1–6.
   PubMedGoogle Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry. 2004;3(1):11.
   PubMedGoogle Scholar
• Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47–53.
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med. Care. 2002;40(8):630–639.
   PubMed Web of Science ®Google Scholar
• Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173–180.
   PubMed Web of Science ®Google Scholar
• Wertheimer AI, Santella TM, Finestone AJ, et al. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther. 2005;22(6):559–577.
   PubMed Web of Science ®Google Scholar
• Zhao J, Ou J, Xue H, et al. Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties. Neuropsychiatr Dis Treat. 2014;10:355–359.
   Web of Science ®Google Scholar
• Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ. 2012;15:531–547.
   PubMedGoogle Scholar
• Li Q, Xiang Y-T, Su Y-A, et al. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China. Aust New Zeal J Psychiatry. 2015;49:129–136.
   PubMed Web of Science ®Google Scholar
• Huang B, Barber SL, Xu M, et al. Make up a missed lesson-new policy to ensure the interchangeability of generic drugs in China. Pharmacol Res Perspect. 2017;5:e00318.
   PubMed Web of Science ®Google Scholar
• Xiao J, Mi W, Li L, et al. High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of China. Neuropsychiatr Dis Treat. 2015;11:1161–1167.
   PubMed Web of Science ®Google Scholar
• Guo X, Fang M, Zhai J, et al. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl). 2011;216:475–484.
   PubMed Web of Science ®Google Scholar
• Guan D, Zhuo D. Comparative study on adverse reactions of the second generation of antipsychotics. Hainan Med J. 2011;22:46–48.
   Google Scholar
• Lin L, Zhao YJ, Zhou HJ, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31:84–92.
   PubMed Web of Science ®Google Scholar
• Novick D, Montgomery W, Treuer T, et al. Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder. Patient Prefer Adher. 2017;11:1019–1025.
   PubMed Web of Science ®Google Scholar
• Wu J, He X, Liu L, et al. Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China. Neuropsychiatr Dis Treat. 2015;11:983–990.
   PubMed Web of Science ®Google Scholar
• Bettonvil B, Kleijnen JPC. Searching for important factors in simulation models with many factors: sequential bifurcation. Eur J Oper Res. 1997;96:180–194.
   Web of Science ®Google Scholar
• Yang L, Li M, Tao L, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Heal. 2009;12:S66–S69.
   PubMed Web of Science ®Google Scholar
• Hu S, Zhang Y, Yang L, et al. Evaluation of the drugs for serious mental illness in National Essential Medicine List of 2012 edition using pharmacoeconomics method. China Licens Pharm. 2013;10:3–10.
   Google Scholar
• Yang L, Tao L. Evidence-based evaluation on cost-effectiveness of second generation antipsychotics. China Pharm. 2007;18:1288–1290.
   Google Scholar
• Guan X, Liu Q, Tang W, et al. Cost-effectiveness analysis of five clinical commonly used atypical antipsychotics as the first-line treatment of first-episode schizophrenia in China based on a decision tree model. Chinese J New Drugs. 2017;26:2101–2106.
   Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7(1):4.
   PubMedGoogle Scholar
• Karagianis J, Grossman L, Landry J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res. 2009;113:41–48.
   PubMed Web of Science ®Google Scholar